TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03385863

Intervention type: DRUG
Intervention: Surfactant, Pulmonary，Curosurf
Description: All NRDS were given an early endotracheal infusion of Curosuf, with an initial dose of 200mg/kg, and if the condition needed to be repeated. Compare the therapeutic effect of pulmonary surfactant of infants at different gestational ages and to investigate whether exogenous surfactant replacement therapy is effective for all newborns with RDS.

Intervention type: DRUG
Intervention: Surfactant, Pulmonary，Curosurf
Description: All NRDS were given an early endotracheal infusion of Curosuf, with an initial dose of 200mg/kg, and if the condition needed to be repeated. Compare the therapeutic effect of pulmonary surfactant of infants at different gestational ages and to investigate whether exogenous surfactant replacement therapy is effective for all newborns with RDS.

Intervention type: DRUG
Intervention: Surfactant, Pulmonary，Curosurf
Description: All NRDS were given an early endotracheal infusion of Curosuf, with an initial dose of 200mg/kg, and if the condition needed to be repeated. Compare the therapeutic effect of pulmonary surfactant of infants at different gestational ages and to investigate whether exogenous surfactant replacement therapy is effective for all newborns with RDS.

Intervention type: OTHER
Intervention: Perinatal risk factors of NRDS
Description: Compare the perinatal risk factors that were closely related to NRDS between early preterm infants with RDS and near term/term infants with RDS.

Intervention type: OTHER
Intervention: Perinatal risk factors of NRDS
Description: Compare the perinatal risk factors that were closely related to NRDS between early preterm infants with RDS and near term/term infants with RDS.

Intervention type: OTHER
Intervention: Perinatal risk factors of NRDS
Description: Compare the perinatal risk factors that were closely related to NRDS between early preterm infants with RDS and near term/term infants with RDS.
Study: NCT04172480

Intervention type: OTHER
Intervention: Blood sampling
Description: Peripheral blood sampling on EDTA

Intervention type: OTHER
Intervention: Blood sampling
Description: Peripheral blood sampling on EDTA

Intervention type: OTHER
Intervention: Blood sampling
Description: Peripheral blood sampling on EDTA
Study: NCT01198938

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin 5 mg sublingually given at 9 p.m. for 5 postoperative days or until discharge
Study: NCT01687335

Intervention type: OTHER
Intervention: answering questionnare in differents time of the treatment
Study: NCT00795158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine
Description: desloratadine 5 mg tablets; one tablet orally once a day for 28 days
Study: NCT04377919

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry
Description: The patients will receive 2 capsules per day containing 500mg of cranberry extract for 8 weeks
Study: NCT02051816

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video Laryngoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apneic Oxygenation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apneic Oxygenation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Apneic Oxygenation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Apneic Oxygenation
Study: NCT01115803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2584702
Description: Supplied as 25 milligrams (mg) and 100 mg capsules, administered orally for two 28-day cycles.
Study: NCT04377919

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will receive 2 capsules per day containing 500mg of maize starch for 8 weeks
Study: NCT03796286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium-fiber bar
Description: Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
Study: NCT01259297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150/300 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150/300 mg once daily
Study: NCT03796286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fiber bar
Description: Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control bar (0 g fiber)
Description: Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
Study: NCT01115803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2584702
Description: Supplied as 25 milligrams (mg) and 100 mg capsules, administered orally for two 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Supplied as 25 mg, 100 mg, or 150 mg tablets, administered orally, daily for two 28-day cycles.~Starting dose is 150mg. Doses may be decreased in 50mg increments if necessary due to toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Supplied as 5 mg or 10 mg tablets, administered orally, daily for two 28-day cycles.
Study: NCT01407042

Intervention type: PROCEDURE
Intervention: mobile-bearing unicondylar knee arthroplasty
Description: mobile-bearing unicondylar knee arthroplasty
Study: NCT00305890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Behavioral Weight Management Program
Description: The lifestyle behavioral weight management program will focus on lifestyle, exercise, attitudes, relationships, and nutrition. Participants will attend 12 weekly group sessions, followed by 6 every-other-week group sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain-Coping Skills Training
Description: The pain-coping skills training will focus on minimizing maladaptive over-reactions and enhancing adaptive strategies to control and decrease pain. Participants will attend 12 weekly group sessions, followed by 6 every-other-week group sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain-Coping Skills Training
Description: The pain-coping skills training will focus on minimizing maladaptive over-reactions and enhancing adaptive strategies to control and decrease pain. Participants will attend 12 weekly group sessions, followed by 6 every-other-week group sessions.
Study: NCT01259297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150/300 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150/300 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Description: HCTZ 12.5/25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Description: HCTZ 12.5/25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Aliskiren
Description: Placebo for Aliskiren 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Aliskiren
Description: Placebo for Aliskiren 300 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Aliskiren
Description: Placebo for Aliskiren 300 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Aliskiren
Description: Placebo for Aliskiren 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Amlodipine
Description: Placebo for Amlodipine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Amlodipine
Description: Placebo for Amlodipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Hydrochlorothiazide (HCTZ)
Description: Placebo for HCTZ 12.5/25 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Hydrochlorothiazide (HCTZ)
Description: Placebo for HCTZ 12.5/25 mg
Study: NCT02771808

Intervention type: OTHER
Intervention: biomarker samples
Description: biomarker samples for haptoglobin genotype (RT-PCR) and phenotype (hemoglobin electrophoresis) general markers for oxidative stress (isoprostane f2 alpha, malondialdehyde) markers of inflammation (CRP, IL-1, 2, 6, 10 and TNF) markers of cardiac injury (CPK, troponins and BNP) markers of kidney injury (cystatin C, creatinine, GFR)
Study: NCT03805295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BOKS Program
Description: 12-week physical activity program, occurring 3x/week, lasting 30-60 minutes per session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BOKS Program
Description: 12-week physical activity program, occurring 3x/week, lasting 30-60 minutes per session.
Study: NCT01084499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femara (Sequence 1)
Description: Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peratra (Sequence 1)
Description: Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femara (Sequence 2)
Description: Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peratra (Sequence 2)
Description: Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.
Study: NCT00638066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin
Description: 500 units of botulinum toxin for the second arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin A
Description: 250 units of botulinum toxin A once
Study: NCT03814317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Treprostinil
Description: Inhaled treprostinil causes dilatation of the pulmonary arteries and may help reduce the pulmonary pressures in this studied population.~All subjects will initiate inhaled treprostinil at a dose of 3 breaths (18 mcg) four times daily. Study drug doses escalations (additional one breath four times daily) can occur every three days with a maximum dosing regimen of up to 12 breaths (72 mcg) four times daily, as clinically tolerated.
Study: NCT01753115

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioThrax
Description: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioThrax
Description: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioThrax
Description: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: 500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: 500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48).
Study: NCT03177876

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus lift implant placement Hydroxyapatite Nano particles
Description: shneiderian membrane elevation and augmentation with Hydroxyapatite Nano particles with simultaneous implant placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sinus lift implant placement tenting
Description: shneiderian membrane elevation and augmentation with graft less tenting technique with simultaneous implant placement
Study: NCT00418262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Titrating with oral administration of 0.25 mg/kg, 0.50 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with food.
Study: NCT01789073

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Impact, Nestlé Health Science
Description: Oral Impact from Nestlé Health Science. An enteral nutritional supplement high in protein and with added immune-enhancing nutrients: arginine, fish oil and nucleotides. The intervention arm receives Oral Impact in an individually estimated dosage according to a protein requirement of 1.5 g/kg bodyweight/day (subtracted their habitual protein intake). Each patient receives this dosage orally the last 7 days prior to surgery.
Study: NCT03132246

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draws
Description: The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draws
Description: The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.
Study: NCT03245632

Intervention type: OTHER
Intervention: Carbapenem-Resistant Klebsiella pneumoniae
Description: no intervention, this is an obervational study.
Study: NCT05104151

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional bar
Description: Protein-based nutritional bar, providing 155 calories per bar

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Habits Intervention
Description: The participants included, will receive a nutritional intervention providing a caloric deficit of 500 calories, depending on their daily requirements, these daily requirements calculated according to the formula BMR (Basic Metabolic Rate). Also prescription of moderate physical activity from 60 to 90 minutes daily will be made.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Habits Intervention
Description: The participants included, will receive a nutritional intervention providing a caloric deficit of 500 calories, depending on their daily requirements, these daily requirements calculated according to the formula BMR (Basic Metabolic Rate). Also prescription of moderate physical activity from 60 to 90 minutes daily will be made.
Study: NCT03196050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handheld Device (Smart Phone)
Description: Handheld device will be used for 3 tasks:~1x per day: status update (how are you today?)~1x per week: 10 questions on general health status~1x per month: EORTC QLQ-C30 questionnaire
Study: NCT03100331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing
Description: Comprehensive neuropsychological assessment and implementation of appropriate support and resources.
Study: NCT04346823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Each participant started by preoxygenation of 100% oxygen for 3minutes. Then, parturients breath 1% of sevoflurane in a mixture of oxygen and air (FIO2 0.5) by tight face mask with a gas flow of 6 L/min.~Thirty seconds after stating inhalation sedation, the obstetrician will be asked to start the procedure.The duration of ECV in addition to the level of difficulty estimated by obstetricians will be recorded. Usually, the duration of ECV does not exceed 10 minutes.~The intervention will be stopped if the woman reported severe pain, if version could not be achieved readily, or if prolonged fetal bradycardia, uterine bleeding or placental abruption occurred.~Parturient will be kept in Post Anesthesia Care Unit (PACU) for 45minutes. CTG will be monitored during PACU stay.
Study: NCT04180436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban 20 mg once daily 8 days
Description: Blood samples for the measurement of rivaroxaban PK parameters

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban 20 mg once daily 8 days
Description: Blood samples for the measurement of rivaroxaban PK parameters

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban 20 mg once daily 8 days
Description: Blood samples for the measurement of rivaroxaban PK parameters

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban 20 mg once daily 8 days
Description: Blood samples for the measurement of rivaroxaban PK parameters
Study: NCT04390698

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paravertebral block
Description: Paravertebral block will be performed at T2,T4 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.4% ropivacaine 20ml at each injection site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opioid free anesthesia
Description: propofol, lidocine and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham block
Description: Local infiltration at the same site of paravertebral block will be performed, with 1% lidocaine 3ml on each injection site.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: opioid general anesthesia
Description: propofol, sufentanil and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained .
Study: NCT04067531

Intervention type: DRUG
Group type: OTHER
Intervention: treatment of BV with first Deqularum and then direkt after with vaginal clindamycin
Description: All patients will get the same treatment
Study: NCT02255786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy (ACT) is an intervention that fosters acceptance of uncomfortable thoughts and emotions as a coping strategy, and encourages engagement in valued behavior in the presence of these emotions. ACT has been successfully applied to parents of children with a variety of mental health presentations.
Study: NCT01943630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15% AS101 gel
Description: Administration of Topical 15% AS101 once a day (overnight)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Administration of Vehicle once a day (overnight)
Study: NCT01072279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tubaramure (Burundi)
Description: Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tubaramure (Burundi)
Description: Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tubaramure (Burundi)
Description: Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procomida (Guatemala)
Description: Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procomida (Guatemala)
Description: Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procomida (Guatemala)
Description: Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procomida (Guatemala)
Description: Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procomida (Guatemala)
Description: Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
Study: NCT04442048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMM-101
Description: Three doses of IMM-101 on days 0, 14, and 45.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: No active treatment. Observation only
Study: NCT03292627

Intervention type: DEVICE
Intervention: Portable Noninvasive Hemodynamic Monitor
Description: A non-invasive monitor for estimating patient's heart contractility and cardiac output by the change of thoracic electrical bioimpedance.

Intervention type: DEVICE
Intervention: Portable Noninvasive Hemodynamic Monitor
Description: A non-invasive monitor for estimating patient's heart contractility and cardiac output by the change of thoracic electrical bioimpedance.
Study: NCT01799382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid on-site evaluation
Description: Rapid on-site evaluation consists on the cytological evaluation of samples obtained during a diagnostic procedure by a pathologist present in the diagnostic suite. In the present study, cytological samples obtained with EBUS-TBNA during bronchoscopy will be evaluated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS-TBNA
Description: EBUS-TBNA is a needle aspiration procedure guided by endobronchial ultrasounds performed during bronchoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Description: EBUS-TBNA is a needle aspiration procedure guided by endobronchial ultrasounds performed during bronchoscopy